ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function
Background Chronic stress is known to promote cancer progression, in part by modulating immune responses through the β2-adrenergic receptor (ADRB2). Inhibiting ADRB2 with β-blockers has demonstrated potential in boosting the effectiveness of immune checkpoint inhibitors across a spectrum of cancers,...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/6/e011611.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850221126891864064 |
|---|---|
| author | Yang Wang Wei Zhang Yu Zhang Ling Chen Shiyu Wang Kun Song Feng Yu Jing Ouyang Shan Cao Cong Peng Dongbo Liu Yingying Dai Wenwu Pei Ziyang Hong Weihua Huang Yijing He Panpan Liu Hanying Yi Gan Zhou Howard McLeod |
| author_facet | Yang Wang Wei Zhang Yu Zhang Ling Chen Shiyu Wang Kun Song Feng Yu Jing Ouyang Shan Cao Cong Peng Dongbo Liu Yingying Dai Wenwu Pei Ziyang Hong Weihua Huang Yijing He Panpan Liu Hanying Yi Gan Zhou Howard McLeod |
| author_sort | Yang Wang |
| collection | DOAJ |
| description | Background Chronic stress is known to promote cancer progression, in part by modulating immune responses through the β2-adrenergic receptor (ADRB2). Inhibiting ADRB2 with β-blockers has demonstrated potential in boosting the effectiveness of immune checkpoint inhibitors across a spectrum of cancers, yet the precise mechanisms remain to be fully elucidated.Methods In vivo and in vitro experiments were performed to evaluate the role of ADRB2 in melanoma models, including its effects on T cells. RNA sequencing analysis highlighted the importance of the transcription factor SRY-related HMG-box 10 (SOX10), which transcriptionally regulates programmed death-ligand 1 (PD-L1). This regulatory role was further validated using luciferase reporter assays and chromatin immunoprecipitation-PCR assays. Mechanistic studies focused on ADRB2 signaling through protein kinase A (PKA) and its downstream target SOX10. To investigate SOX10’s role in mediating the effects of ADRB2, knockdown and overexpression experiments were conducted. Additionally, similar studies in colorectal cancer (CRC) models confirmed the conserved function of the ADRB2-SOX10-PD-L1 axis.Results This study explores the role of ADRB2 in regulating tumor PD-L1 expression and T cell functionality, offering insights for cancer immunotherapy. Clinical data revealed that patients with melanoma with high ADRB2 expression responded better to programmed cell death protein 1 inhibitors. In melanoma models, ADRB2 inhibition reduced PD-L1 expression, enhanced T cell infiltration, and promoted antitumor immunity, while ADRB2 activation had the opposite effect. Mechanistically, ADRB2 signaling through PKA upregulated SOX10, which transcriptionally modulates PD-L1. SOX10 knockdown replicated the effects of ADRB2 inhibition, while SOX10 overexpression reversed them. Similar findings in CRC models confirmed the conserved role of the ADRB2-SOX10-PD-L1 axis. Targeting ADRB2 and SOX10 may enhance immune checkpoint inhibitor efficacy in cancer treatment.Conclusions These findings underscore the potential of ADRB2 and SOX10 as therapeutic targets for mitigating stress-induced immunosuppression and for augmenting the effectiveness of immunotherapies in a variety of cancer types. |
| format | Article |
| id | doaj-art-714fbf5dd5ba40479586f652a6e04c5f |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-714fbf5dd5ba40479586f652a6e04c5f2025-08-20T02:06:47ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-06-0113610.1136/jitc-2025-011611ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell functionYang Wang0Wei Zhang1Yu Zhang2Ling Chen3Shiyu Wang4Kun Song5Feng Yu6Jing Ouyang7Shan Cao8Cong Peng9Dongbo Liu10Yingying Dai11Wenwu Pei12Ziyang Hong13Weihua Huang14Yijing He15Panpan Liu16Hanying Yi17Gan Zhou18Howard McLeod193 Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China2 Department of Gastrointestinal Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China5 Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Central South University, Changsha, Hunan, China2 Department of Gastrointestinal Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China4 Department of Dermatology, Xiangya Hospital Central South University, Changsha, Hunan, China5 Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China2 Department of Gastrointestinal Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China2 Department of Gastrointestinal Surgery, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China5 Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Central South University, Changsha, Hunan, China4 Department of Dermatology, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, China1 Department of Clinical Pharmacology, Xiangya Hospital Central South University, Changsha, Hunan, ChinaBackground Chronic stress is known to promote cancer progression, in part by modulating immune responses through the β2-adrenergic receptor (ADRB2). Inhibiting ADRB2 with β-blockers has demonstrated potential in boosting the effectiveness of immune checkpoint inhibitors across a spectrum of cancers, yet the precise mechanisms remain to be fully elucidated.Methods In vivo and in vitro experiments were performed to evaluate the role of ADRB2 in melanoma models, including its effects on T cells. RNA sequencing analysis highlighted the importance of the transcription factor SRY-related HMG-box 10 (SOX10), which transcriptionally regulates programmed death-ligand 1 (PD-L1). This regulatory role was further validated using luciferase reporter assays and chromatin immunoprecipitation-PCR assays. Mechanistic studies focused on ADRB2 signaling through protein kinase A (PKA) and its downstream target SOX10. To investigate SOX10’s role in mediating the effects of ADRB2, knockdown and overexpression experiments were conducted. Additionally, similar studies in colorectal cancer (CRC) models confirmed the conserved function of the ADRB2-SOX10-PD-L1 axis.Results This study explores the role of ADRB2 in regulating tumor PD-L1 expression and T cell functionality, offering insights for cancer immunotherapy. Clinical data revealed that patients with melanoma with high ADRB2 expression responded better to programmed cell death protein 1 inhibitors. In melanoma models, ADRB2 inhibition reduced PD-L1 expression, enhanced T cell infiltration, and promoted antitumor immunity, while ADRB2 activation had the opposite effect. Mechanistically, ADRB2 signaling through PKA upregulated SOX10, which transcriptionally modulates PD-L1. SOX10 knockdown replicated the effects of ADRB2 inhibition, while SOX10 overexpression reversed them. Similar findings in CRC models confirmed the conserved role of the ADRB2-SOX10-PD-L1 axis. Targeting ADRB2 and SOX10 may enhance immune checkpoint inhibitor efficacy in cancer treatment.Conclusions These findings underscore the potential of ADRB2 and SOX10 as therapeutic targets for mitigating stress-induced immunosuppression and for augmenting the effectiveness of immunotherapies in a variety of cancer types.https://jitc.bmj.com/content/13/6/e011611.full |
| spellingShingle | Yang Wang Wei Zhang Yu Zhang Ling Chen Shiyu Wang Kun Song Feng Yu Jing Ouyang Shan Cao Cong Peng Dongbo Liu Yingying Dai Wenwu Pei Ziyang Hong Weihua Huang Yijing He Panpan Liu Hanying Yi Gan Zhou Howard McLeod ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function Journal for ImmunoTherapy of Cancer |
| title | ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function |
| title_full | ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function |
| title_fullStr | ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function |
| title_full_unstemmed | ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function |
| title_short | ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function |
| title_sort | adrb2 inhibition suppresses cancer immune evasion by regulating tumor sox10 pd l1 axis and t cell function |
| url | https://jitc.bmj.com/content/13/6/e011611.full |
| work_keys_str_mv | AT yangwang adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT weizhang adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT yuzhang adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT lingchen adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT shiyuwang adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT kunsong adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT fengyu adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT jingouyang adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT shancao adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT congpeng adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT dongboliu adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT yingyingdai adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT wenwupei adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT ziyanghong adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT weihuahuang adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT yijinghe adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT panpanliu adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT hanyingyi adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT ganzhou adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction AT howardmcleod adrb2inhibitionsuppressescancerimmuneevasionbyregulatingtumorsox10pdl1axisandtcellfunction |